基于兔VX2原位移植肺癌模型评价多西他赛脂质体疗效和安全性

刘宇; 张福军; 兰作平; 张梨; 王杰; 余瑜

doi:10.16016/j.1000-5404.201611128

您当前的位置：

首页 >

文章列表页 >

基于兔VX2原位移植肺癌模型评价多西他赛脂质体疗效和安全性

基础医学 | 更新时间：2026-01-09

- 基于兔VX2原位移植肺癌模型评价多西他赛脂质体疗效和安全性
- Efficacy and safety evaluation of docetaxel liposome inarabbit model bearing orthotopically transplanted VX2 tumor
- 第三军医大学学报 2017年39卷第14期页码：1428-1434
- 作者机构：
  
  1.400016 重庆，重庆医科大学：附属第一医院药学部
  2.400016 重庆，重庆医科大学：附属第一医院口腔颌面外科
  3.400016 重庆，重庆医科大学：药学院药物化学与生物材料研究室
- 作者简介：
  
  [余瑜, E-mail:yuyu3519@163.com YU Yu, E-mail:yuyu3519@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81172097);重庆市自然科学基金重点项目(CSTC2013jjB0010)
- DOI：10.16016/j.1000-5404.201611128
  中图分类号： R734.2; R969.4; R979.1
- 收稿：2016-11-13，
  
  修回：2017-02-03，
  
  纸质出版：2017-07-30
- 稿件说明：
移动端阅览
刘宇, 张福军, 兰作平, 等. 基于兔VX2原位移植肺癌模型评价多西他赛脂质体疗效和安全性[J]. 第三军医大学学报, 2017,39(14):1428-1434.

Yu LIU, Fujun ZHANG, Zuoping LAN, et al. Efficacy and safety evaluation of docetaxel liposome inarabbit model bearing orthotopically transplanted VX2 tumor[J]. Journal of Third Military Medical University, 2017, 39(14): 1428-1434.
刘宇, 张福军, 兰作平, 等. 基于兔VX2原位移植肺癌模型评价多西他赛脂质体疗效和安全性[J]. 第三军医大学学报, 2017,39(14):1428-1434. DOI： 10.16016/j.1000-5404.201611128.

Yu LIU, Fujun ZHANG, Zuoping LAN, et al. Efficacy and safety evaluation of docetaxel liposome inarabbit model bearing orthotopically transplanted VX2 tumor[J]. Journal of Third Military Medical University, 2017, 39(14): 1428-1434. DOI： 10.16016/j.1000-5404.201611128.

摘要

目的

评价多西他赛脂质体(DTX-LP)的远期疗效和不良反应。

方法

建立兔VX2原位移植肺癌模型，分别静脉给予荷瘤兔空白脂质体(BLA-LP)、多西他赛注射剂(DTX-IN，2.7 mg/kg)、DTX-LP高剂量(0.9 mg/kg)、DTX-LP中剂量(0.3 mg/kg)以及DTX-LP低剂量(0.1 mg/kg)治疗4周期，记录兔生存时间并作生存分析，考察兔存活期间体质量及白细胞计数变化率，食欲减退、腹泻、肠道出血发生率，实验兔死亡后作大体解剖，评估主要脏器的组织病理损害程度。

结果

BLA-LP组，DTX-IN组，DTX-LP高、中、低剂量组兔的中位生存时间分别为28、35、49、34、32 d。生存曲线经Log-Rank检验，DTX-LP高剂量组分别与BLA-LP组、DTX-IN组比较，差异有统计学意义(

=0.001，

=0.005)。上述各治疗组兔的平均体质量变化率分别为(-23.03±7.99)%、(-11.25±9.67)%、(-1.48±6.36)%、(-2.08±14.39)%和(-17.27±18.41)%；白细胞计数累积变化率分别为(-3.53±18.17)%、(-52.78±12.50)%、(-16.56±10.21)%、(-22.19±10.70)%和(-15.37±14.14)%。DTX-IN组和DTX-LP高剂量组食欲减退的发生率分别为83.3%和50.0%；BLA-LP组、DTX-IN组及DTX-LP高、中、低剂量组腹泻发生率分别为16.7%、66.7%、33.3%、16.7%、16.7%；DTX-IN组肠道出血发生率83.3%。病理检查结果显示DTX-LP高剂量组的心、肝、脾、肺、肾组织无明显异常，DTX-IN组上述脏器均有不同程度的病理损害。

结论

DTX-LP高剂量组明显延长VX2肺癌兔中位生存期，且不良反应轻微。

Abstract

Objective

To evaluate the long-term efficacy and safety of docetaxel liposome(DTX-LP) in a rabbit model of lung cancer.

Methods

Thirty rabbit models of lung cancer established by orthotopic transplantation of VX2 tumor tissues were randomized in 5 equal groups to receive intravenous injections of blank liposome (BLA-LP)

docetaxel (DTX-IN

2.7 mg/kg)

or DTX-LP at high (0.9 mg/kg)

moderate (0.3 mg/kg) or low (0.1 mg/kg) doses once a week for 4 consecutive weeks

and the survival time of the rabbits was recorded. The survival of the rabbits in each group was estimated using Kaplan-Meier analysis and analyzed with Log-rank test. The changes in body weight and leukocyte count of the rabbits were observed

and the incidence of anorexia

diarrhea and intestinal bleeding were evaluated. After the rabbits died

the heart

liver

spleen

lungs and kidneys were dissected for histopathological examinations.

Results

The median survival time of the rabbits was 28 d in BLA-LP group

35 d in DTX-IN group

49 d in high-dose DTX-LP group

34 d in moderate-dose DTX-LP group and 32 d in low-dose

DTX-LP group. The survival rate of the rabbits was significantly higher in high-dose DTX-LP group than in BLA-LP group (

=0.001) and DTX-IN group (

=0.005). The percent change in the body weight in the 5 groups was (-23.03±7.99)%

(-11.25±9.67)%

(-1.48±6.36)%

(-2.08±14.39)% and (-17.27±18.41)%

respectively

and that of leukocyte count was (-3.53±18.17)%

(-52.78±12.50)%

(-16.56±10.21)%

(-22.19±10.70)% and (-15.37±14.14%)

respectively. The incidence of anorexia was 83.3% in DTX-IN group and 50.0% in high-dose DTX-LP group. The incidence of diarrhea was 16.7%

66.7%

33.3%

16.7% and 16.7% in the 5 groups

respectively

and intestinal bleeding occurred in DTX-IN group was 83.3%. Histological examination revealed obvious pathological changes in the heart

liver

spleen

lungs and kidneys in DTX-IN group but not in high-dose DTX-LP group.

Conclusion

Treatment with high-dose DTX-LP significantly prolongs the survival of tumor-bearing rabbits with only mild adverse effects.

关键词

Keywords

references

FULTON B, SPENCER C M. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer[J]. Drugs, 1996, 51(6): 1075-1092.

CHU Q, VINCENT M, LOGAN D, et al . Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline[J ] . Lung Cancer, 2005, 50(3): 355-374. DOI: 10.1016/j.lungcan.2005.06.010.

MONTERO A, FOSSELLA F, HORTOBAGYI G, et al . Docetaxel for treatment of solid tumours: a systematic review of clinical data[J ] . Lancet Oncol, 2005, 6(4): 229-239. DOI: 10.1016/S1470-2045(05)70094-2.

ZHAO L, WEI Y, LI W, et al . Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted deliver system: in vitro and vivo evaluation[J ] . J Drug Target, 2011, 19(3): 171-178. DOI: 10.3109/10611861003801859.

ZHAO L, WEI Y M, ZHONG X D, et al .PK and tissue distribution of docetaxel in rabbits after i.v administration of liposomal and injectable formulation[J ] . J Pharm Biomed Anal, 2009, 49(4):989-996. DOI: 10.1016/j.jpba.2009.01.016.

刘宇, 邱峰, 吕志祥, 等. 99m 锝标记多西他赛脂质体的制备及其在兔体内的组织分布研究[J ] .第三军医大学学报, 2016, 38(21): 2303-2308. DOI: 10.16016/j.1000-5404.201605002.

LIU Y, QIU F, LYU Z X, et al . Preparation of technetium labeled docetaxel liposome and its distribution in rabbits[J ] . J Third Mil Med Univ, 2016, 38(21): 2303-2308. DOI: 10.16016/j.1000-5404.201605002.

刘宇, 兰作平, 张福军, 等.快速微创建立弥漫型兔VX2肺癌模型及其生物学行为研究[J].重庆医科大学学报, 2011, 36(9): 1025-1028.

LIU Y, LAN Z P, ZHANG F J, et al . Study on establishment of rabbit vx2 diffuse lung cancer model with minimally invasive surgery and biological behavior of the tumor[J ] . J Chongqing Med Univ, 2011, 36(9): 1025-1028.

KIM G M, KIM M D, KIM DO Y, et al . Transarterial chemoembolization using sorafenib in a rabbit vx2 liver tumor model: pharmacokinetics and antitumor effect[J ] . J Vasc Interv Radiol, 2016, 27(7): 1086-1092. DOI: 10.1016/j.jvir.2016.02.032.

MENG M, GAO J, WU C, et al . Doxorubicin nanobubble for comb ining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor[J ] . Tumour Biol, 2016, 37(7): 8673-8680. DOI: 10.1007/s13277-015-4525-5.

KONDO K, FUJINO H, MIYOSHI T, et al . Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drugeffects[J ] . Oncol Rep, 2004, 12(5): 991-999.

BISSERY M C, NOHYNEK G, SANDERINK G J, et al . Docetaxel (Taxotere): a review of preclinical and clinical experience. Part Ⅰ: preclinical experience[J ] . AntiCancer Drugs, 1995, 6(3): 339-355, 363-368.

KIDD J G, ROUS P. Cancer deriving from the virus papillomas of wild rabbits under natural conditions[J]. J Exp Med, 1940, 71(4): 469-494.

BAGULEY B C. Multidrug Resistance in Cancer[J]. Methods Mol Biol, 2010, 596: 1-14.DOI: 10.1007/978-1-60761-416-6_1.

SZAKáCS G, PATERSON J K, LUDWIG J A, et al . Targeting multidrug resistance in cancer[J ] . Nat Rev Drug Discov, 2006, 5(3): 219-234. DOI:10.1038/nrd1984.

ZHOU J, ZHAO W Y, MA X, et al . The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer[J ] . Biomaterials, 2013, 34(14): 3626-3638. DOI: 10.1016/j.biomaterials.2013.01.078.

LI X T, ZHOU Z Y, JIANG Y, et al . PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer[J ] . J Drug Target, 2015, 23(3): 232-243. DOI: 10.3109/1061186x.2014.979829.

RAHMAN Y E, HANSON W R, BHARUCHA J, et al . Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation[J ] . Ann N Y Acad Sci, 1978, 308: 325-342. DOI: 10.1111/j.1749-6632.1978.tb22033.x.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

^99m锝标记多西他赛脂质体的制备及其在兔体内的组织分布研究

多西他赛用于实体瘤患者的群体药代动力学研究

注射用右旋雷贝拉唑钠在健康人体内的药代动力学和药效学研究

CREKA肽修饰的载多西他赛脂质体抗前列腺癌靶向研究

不同剂量注射用泮托拉唑钠在健康人体内的药代动力学和药效学研究